Supreme Court Ban Sends Patanjali Shares Tumbling Amid Misleading Advertisements Controversy

Patanjali, the popular Ayurvedic products brand, faced a sharp decline in its share price on Wednesday following a landmark ruling by the Supreme Court. Here's a breakdown of the key developments:

1. Interim Order and Ban on Advertisements:

   • The Supreme Court issued an interim order banning advertisements of products by Patanjali Ayurved, citing concerns over allegedly misleading claims regarding their medicinal properties.
   • The bench criticised Patanjali for promoting medicines claiming to cure diseases without empirical evidence, leading to the ban on advertising such products until further notice.

2. Contempt Notice to Founders:

   • Patanjali's founders, Baba Ramdev and Acharya Balkrishna, received a contempt of court notice for allegedly flouting previous court orders by propagating false and misleading claims about their products.
   • The notice requires a response from the founders within two weeks, highlighting the seriousness of the allegations and the court's commitment to upholding truth in advertising.

3. Implications and Regulatory Scrutiny:

   • The ban on advertising specific medicinal products underscores the Supreme Court's commitment to protecting consumers from misleading claims and ensuring the integrity of the healthcare industry.
   • The Court's criticism of the AYUSH Ministry for ineffective regulation of misleading advertisements highlights the need for robust oversight and enforcement measures.

4. Financial Impact and Response:

   • Patanjali responded to the Supreme Court order, stating that it would not affect the financial performance of its food arm, Patanjali Foods, which operates in edible oil and food FMCG products.
   • Despite this assurance, the ban on advertising could impact consumer confidence and brand reputation, potentially leading to long-term repercussions for Patanjali's market position.

5. Industry Reaction and Public Concern:

   • The ruling has sparked discussions about the accountability of companies in the healthcare sector and the importance of evidence-based marketing practices.
   • Consumers and industry stakeholders have expressed concern over the proliferation of misleading advertisements and the need for stricter regulations to safeguard public health and well-being.

As the controversy unfolds, investors, regulators, and consumers closely monitor developments surrounding Patanjali's advertising practices and the broader implications for the advertising and healthcare industries. The Supreme Court's decisive action underscores the imperative of transparency and accountability in advertising, signaling a pivotal moment in the ongoing discourse on consumer protection and corporate responsibility.